Evidence map›Paper›PMID 42087393›Full record

ArticleJournal of proteome research2026

Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer.

Hanfeng Lin, Yen-Yu Yang, Sudipa Maity, Qingyu Sun, Jin Wang

Abstract read
In one paragraph

Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hanfeng LinThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
Yen-Yu YangThermo Fisher Scientific, San Jose, California 95134, United States.
Sudipa MaityThermo Fisher Scientific, San Jose, California 95134, United States.
Qingyu SunThermo Fisher Scientific, San Jose, California 95134, United States.
Jin WangThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.ORCID 0000-0003-3625-7919

Funding

Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell MalignanciesR01CA250503 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WANG, JIN, WANG, MICHAEL · 2020 to 2024
$3.4M
NCI NIH HHS R01 CA250503
6 · The paper itself

Abstract

Targeted protein degradation (TPD) is a therapeutic strategy that utilizes small molecules to induce the proximity-driven degradation of disease-causing proteins. Because the efficacy and selectivity of TPD compounds must be validated across thousands of proteins, high-throughput proteomics is essential for the rapid screening and characterization of these novel degraders. Here, we developed a 300 samples per day (SPD) LC-MS/MS method using the Orbitrap Astral mass spectrometer for ultrahigh-throughput TPD compound screening. We identified close to 8000 protein groups from a single cell line with a coefficient of variation (CV) of less than 10%, highlighting the deep proteome coverage and method reproducibility even at 300 SPD. This high degree of precision provides the statistical confidence to detect subtle, yet significant, changes in protein abundance that were previously challenging to quantify in high-throughput workflows. To evaluate the quantitation accuracy of this method, we further mixed the digests from two or three species at different ratios. Our three-proteome mixture results demonstrated highly accurate quantitation for proteins with both small and large fold changes. Moreover, our two-proteome mixture experiment, where 20 to 160 ng of yeast digest was spiked into 200 ng of HeLa digest, showed an R

Indexed as

High-Throughput Screening AssaysLiquid Chromatography-Mass SpectrometryProteolysisProteomeProteomicsTandem Mass SpectrometryChromatography, LiquidHumansReproducibility of ResultsSaccharomyces cerevisiaeThalidomideProteomeThalidomidechemoproteomicshigh-throughput screeningmolecular glueOrbitrap Astralquantitative proteomicstargeted protein degradation

Identifiers

PMID42087393
PMCPMC13614527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.